Yu Zhang

Dr. Yu Zhang's research operates at the intersection of AI, translational neuroscience, and precision medicine. His work focuses on unraveling the complex neurobiological mechanisms underlying cognitive deficits, behavioral dysfunctions, and therapeutic responses in mental health disorders. By integrating advanced machine learning techniques with multimodal brain imaging modalities (e.g., fMRI, DTI, EEG), Dr. Zhang aims to identify neural signatures that reveal the heterogeneity of mental disorders across individuals. A central goal of his research is the development and validation of robust neurobiomarkers to improve diagnostic accuracy, refine prognostic assessments, and guide personalized treatment strategies. His work systematically characterizes brain function and dysfunction to optimize therapeutic interventions, including pharmacological treatments, psychotherapy, and neurostimulation. He is particularly focused on conditions such as Alzheimer’s disease, mood disorders, and neurodevelopmental disorders, where individualized approaches are essential for improving patient outcomes.

Dr. Zhang has received several grants including the R01, R21, and Alzheimer's Association AARG grant. Beyond foundational research, Dr. Zhang is committed to bridging the gap between computational innovation and clinical application. By collaborating with clinicians, neuroscientists, and engineers, he strives to translate data-driven insights into actionable tools for real-world healthcare settings. His long-term vision is to enable mental health diagnostics and treatment to be guided by objective, biologically grounded biomarkers, thereby enhancing quality of life and long-term outcomes for individuals with psychiatric and neurological conditions.

The Stanford Precision NeuroIntelligence (SPNI) Lab, led by Dr. Zhang, is dedicated to advancing research in AI-driven neuroimaging and precision psychiatry. The lab develops and applies cutting-edge machine learning and deep learning methods to uncover neurobiological mechanisms associated with cognitive and behavioral dysfunctions, as well as treatment responses in mental health conditions. Its mission is to identify translational biomarkers that support precision diagnosis, prognosis, and targeted interventions for mood disorders, neurodevelopmental disorders, and neurodegenerative diseases.